|Title||Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study.|
|Publication Type||Journal Article|
|Year of Publication||2022|
|Authors||Wang, L, Scherer, SE, Bielinski, SJ, Muzny, DM, Jones, LA, Black, JLogan, Moyer, AM, Giri, J, Sharp, RR, Matey, ET, Wright, JA, Oyen, LJ, Nicholson, WT, Wiepert, M, Sullard, T, Curry, TB, Vitek, CRRohrer, McAllister, TM, St Sauver, JL, Caraballo, PJ, Lazaridis, KN, Venner, E, Qin, X, Hu, J, Kovar, CL, Korchina, V, Walker, K, Doddapaneni, H, Wu, T-J, Raj, R, Denson, S, Liu, W, Chandanavelli, G, Zhang, L, Wang, Q, Kalra, D, Karow, MBeth, Harris, KJ, Sicotte, H, Peterson, SE, Barthel, AE, Moore, BE, Skierka, JM, Kluge, ML, Kotzer, KE, Kloke, K, Pol, JMVander, Marker, H, Sutton, JA, Kekic, A, Ebenhoh, A, Bierle, DM, Schuh, MJ, Grilli, C, Erickson, S, Umbreit, A, Ward, L, Crosby, S, Nelson, EA, Levey, S, Elliott, M, Peters, SG, Pereira, N, Frye, M, Shamoun, F, Goetz, MP, Kullo, IJ, Wermers, R, Anderson, JA, Formea, CM, Melik, RMEl, Zeuli, JD, Herges, JR, Krieger, CA, Hoel, RW, Taraba, JL, St Thomas, SR, Absah, I, Bernard, ME, Fink, SR, Gossard, A, Grubbs, PL, Jacobson, TM, Takahashi, P, Zehe, SC, Buckles, S, Bumgardner, M, Gallagher, C, Fee-Schroeder, K, Nicholas, NR, Powers, ML, Ragab, AK, Richardson, DM, Stai, A, Wilson, J, Pacyna, JE, Olson, JE, Sutton, EJ, Beck, AT, Horrow, C, Kalari, KR, Larson, NB, Liu, H, Wang, L, Lopes, GS, Borah, BJ, Freimuth, RR, Zhu, Y, Jacobson, DJ, Hathcock, MA, Armasu, SM, McGree, ME, Jiang, R, Koep, TH, Ross, JL, Hilden, MG, Bosse, K, Ramey, B, Searcy, I, Boerwinkle, E, Gibbs, RA, Weinshilboum, RM|
|Date Published||2022 May|
|Keywords||Academic Medical Centers, Base Sequence, Cytochrome P-450 CYP2D6, Genotype, Humans, Pharmacogenetics|
PURPOSE: The Mayo-Baylor RIGHT 10K Study enabled preemptive, sequence-based pharmacogenomics (PGx)-driven drug prescribing practices in routine clinical care within a large cohort. We also generated the tools and resources necessary for clinical PGx implementation and identified challenges that need to be overcome. Furthermore, we measured the frequency of both common genetic variation for which clinical guidelines already exist and rare variation that could be detected by DNA sequencing, rather than genotyping.
METHODS: Targeted oligonucleotide-capture sequencing of 77 pharmacogenes was performed using DNA from 10,077 consented Mayo Clinic Biobank volunteers. The resulting predicted drug response-related phenotypes for 13 genes, including CYP2D6 and HLA, affecting 21 drug-gene pairs, were deposited preemptively in the Mayo electronic health record.
RESULTS: For the 13 pharmacogenes of interest, the genomes of 79% of participants carried clinically actionable variants in 3 or more genes, and DNA sequencing identified an average of 3.3 additional conservatively predicted deleterious variants that would not have been evident using genotyping.
CONCLUSION: Implementation of preemptive rather than reactive and sequence-based rather than genotype-based PGx prescribing revealed nearly universal patient applicability and required integrated institution-wide resources to fully realize individualized drug therapy and to show more efficient use of health care resources.
|Alternate Journal||Genet Med|
|PubMed Central ID||PMC9272414|
|Grant List||U19 GM061388 / GM / NIGMS NIH HHS / United States |
R01 AG034676 / AG / NIA NIH HHS / United States
R01 GM028157 / GM / NIGMS NIH HHS / United States
R33 AG058738 / AG / NIA NIH HHS / United States
U01 HG005137 / HG / NHGRI NIH HHS / United States
U01 HG006379 / HG / NHGRI NIH HHS / United States
R01 GM125633 / GM / NIGMS NIH HHS / United States